Citation
Pizzorno, Andrés, et al. "In Vitro Evaluation of Antiviral Activity of Single and Combined Repurposable Drugs Against SARS-CoV-2." Antiviral Research, vol. 181, 2020, p. 104878.
Pizzorno A, Padey B, Dubois J, et al. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. Antiviral Res. 2020;181:104878.
Pizzorno, A., Padey, B., Dubois, J., Julien, T., Traversier, A., Dulière, V., Brun, P., Lina, B., Rosa-Calatrava, M., & Terrier, O. (2020). In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. Antiviral Research, 181, 104878. https://doi.org/10.1016/j.antiviral.2020.104878
Pizzorno A, et al. In Vitro Evaluation of Antiviral Activity of Single and Combined Repurposable Drugs Against SARS-CoV-2. Antiviral Res. 2020;181:104878. PubMed PMID: 32679055.
TY - JOUR
T1 - In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.
AU - Pizzorno,Andrés,
AU - Padey,Blandine,
AU - Dubois,Julia,
AU - Julien,Thomas,
AU - Traversier,Aurélien,
AU - Dulière,Victoria,
AU - Brun,Pauline,
AU - Lina,Bruno,
AU - Rosa-Calatrava,Manuel,
AU - Terrier,Olivier,
Y1 - 2020/07/15/
PY - 2020/05/06/received
PY - 2020/07/06/revised
PY - 2020/07/07/accepted
PY - 2020/7/18/pubmed
PY - 2020/9/8/medline
PY - 2020/7/18/entrez
KW - Antivirals
KW - Berberine
KW - COVID-19
KW - Diltiazem
KW - Drug combination
KW - Remdesivir
SP - 104878
EP - 104878
JF - Antiviral research
JO - Antiviral Res
VL - 181
N2 - In response to the current pandemic caused by the novel SARS-CoV-2, identifying and validating effective therapeutic strategies is more than ever necessary. We evaluated the in vitro antiviral activities of a shortlist of compounds, known for their cellular broad-spectrum activities, together with drugs that are currently under evaluation in clinical trials for COVID-19 patients. We report the antiviral effect of remdesivir, lopinavir, chloroquine, umifenovir, berberine and cyclosporine A in Vero E6 cells model of SARS-CoV-2 infection, with estimated 50% inhibitory concentrations of 0.99, 5.2, 1.38, 3.5, 10.6 and 3 μM, respectively. Virus-directed plus host-directed drug combinations were also investigated. We report a strong antagonism between remdesivir and berberine, in contrast with remdesivir/diltiazem, for which we describe high levels of synergy, with mean Loewe synergy scores of 12 and peak values above 50. Combination of host-directed drugs with direct acting antivirals underscore further validation in more physiological models, yet they open up interesting avenues for the treatment of COVID-19.
SN - 1872-9096
UR - https://www.unboundmedicine.com/medline/citation/32679055/In_vitro_evaluation_of_antiviral_activity_of_single_and_combined_repurposable_drugs_against_SARS_CoV_2_
DB - PRIME
DP - Unbound Medicine
ER -